查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439554

用於癌症診斷的液體活檢 - 全球市場考慮、競爭格局、市場預測 (2030)

Liquid Biopsy in Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按訂單生產 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

全球癌症診斷液體活檢市場規模將於 2023 年達到 76.4 億美元，到 2030 年將達到 192.4 億美元，預計 2024-2030 年期間複合年增長率為 16.64%。 各種癌症盛行率上升、微創手術需求增加、精準醫療需求增加以及產品開發技術創新等因素預計將推動癌症診斷液體活檢市場的發展。

癌症診斷液體切片的市場動態

用於癌症診斷的液體活檢市場的主要驅動因素之一是，由於癌症發病率的增加，對用於癌症診斷的液體活檢的需求不斷增長。 根據國際癌症研究機構進行的 GLOBOCAN 研究，估計 2020 年全球報告了 1,930 萬新癌症病例和約 1,000 萬癌症死亡病例。 此外，根據上述資料，肺癌仍是2020年癌症死亡的第一大原因，估計死亡人數為180萬人（18%），其次是大腸直腸癌（9.4%）和肝癌。（8.3%）、胃癌（ 7.7%）和女性乳癌（6.9%）。 考慮到世界各地新癌症患者數量不斷增加，我們正在開發傳統活檢的替代方法，以加快癌症診斷過程，並使患者和醫療保健專業人員更順利。人們越來越重視開發方法。 此外，液體活檢在肺癌和乳癌等治療管理中的應用預計將進一步推動產品需求。 因此，癌症患者數量的增加預計將導致對液體活檢產品和服務的需求增加。 因此，所有上述因素預計將有助於癌症診斷液體活檢市場的成長。

此外，導致癌症診斷液體活檢需求擴大的另一個主要因素是精準醫學在癌症治療中日益重要。 "精準醫療" 的概念，即根據腫瘤的生物學行為制定個人化治療方案，被認為是癌症治療的新方法。 精準醫學的臨床應用廣泛，包括篩檢、診斷、預後預測、治療反應/抗藥性預測、復發和轉移的早期檢測以及癌症生物分層等。 液體活檢由於能夠提供原發性和轉移性腫瘤的多個非侵入性全局快照，因此在個人化醫療方面具有巨大的前景。 針對患者健康狀況的客製化治療已獲得醫生的廣泛接受和關注。 液體活檢在為患者開發個人化治療方面發揮著重要作用。 液體活檢即時提供有關腫瘤概況的重要信息，並幫助確定後續治療步驟。 液體活檢的潛力得到了市場參與者的認可，這一領域的產品開發興趣日益濃厚就證明了這一點。 例如，2022 年 9 月，德國公司 Molecular Health GmbH 與韓國新創公司 EONE-Diagnomics Genome Center (EDGC) 合作，幫助其醫療保健提供者客戶確定癌症患者的個人化治療方案。我使其成為可能。 因此，精準醫學的日益重要性和液體活檢的優勢預計將有助於預測期內用於癌症診斷的液體活檢市場的成長。

然而，由於技術限制和缺乏技術標準化而導致錯誤結果的風險可能會對癌症診斷液體活檢市場的成長帶來一定的挑戰。

在用於癌症診斷的液體活檢市場中，由於採取控制COVID-19傳播的措施，收入有所下降。 COVID-19 爆發期間的主要措施之一是暫停許多選擇性手術和門診就診。 這項措施減少了市場對液體活檢產品和服務的需求，因為在封鎖初期，世界各地的醫療保健系統指南暫時專注於管理 COVID-19 患者數量。

本報告研究和分析了全球癌症診斷液體活檢市場，提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。

目錄

第1章癌症診斷液體切片市場報告介紹

第2章癌症診斷液體切片市場概要

  • 調查範圍
  • 市場概覽
  • 競爭評估
  • 財務基準

第3章監理與專利分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第4章癌症診斷液體切片市場主要因素分析

  • 推動癌症診斷市場的因素
    • 各種癌症的發生率不斷增加
    • 對微創手術的需求不斷增加
    • 日益關注精準醫療
    • 產品開發中的技術創新
  • 癌症診斷市場的限制與挑戰
    • 結果不正確的風險
    • 程序缺乏標準化
  • 癌症診斷的液體活檢市場機會
    • 液體切片在臨床實務的應用有限
    • 擴大新興經濟體的市場覆蓋範圍

第5章癌症診斷液體切片市場的波特五力分析

第6章COVID-19對癌症診斷液體切片市場的影響分析

第7章癌症診斷液體切片市場佈局

  • 依類型
    • 產品
    • 服務
  • 依樣本類型
    • 血
    • 尿液
    • 唾液
  • 依生物標記類型
    • CTC
    • ctDNA
    • cfDNA
    • 其他
  • 依癌症類型
    • 肺癌
    • 乳癌
    • 大腸癌
  • 按技術
    • 聚合□鍊式反應
    • 次世代定序
  • 按最終用戶
    • 醫院
    • 診斷中心
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他領域

第8章癌症診斷液體切片市場的公司與產品概況

  • Myriad Genetics Inc
  • Exact Sciences Corporation
  • Biocartis
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc
  • Biocept Inc
  • Agilent Technologies Inc
  • MDx Health
  • Neogenomics Laboratories
  • F. Hoffman La Roche Ltd
  • Guardant Health
  • Bio-Techne
  • Illumina Inc
  • QIAGEN
  • Lucence Health Inc
  • Personal Genome Diagnostics Inc
  • SAGA Diagnostics
  • Agena Bioscience Inc
  • The Menarini Group
  • MiRXES Pte Ltd.

第9章KOL瀏覽量

第 10 章參考文獻

第 10 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

Product Code: DIMDCL0380

Liquid Biopsy in Cancer Diagnostics Market By Type (Product Type [Instruments And Reagents & Kits] And Services), By Sample Type (Blood, Urine, And Saliva), By Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, And Others), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, And Others), By Technique (Polymerase Chain Reaction And Next Generation Sequencing), By End User (Hospitals, Diagnostic Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of cancers and growing popularity of precision medicine

Global liquid biopsy in cancer diagnostics market was valued at USD 7.64 billion in 2023, growing at a CAGR of 16.64% during the forecast period from 2024 to 2030 to reach USD 19.24 billion by 2030. Factors such as the rising incidence of various cancers, growing demand for minimally invasive procedures, increasing demand of precision medicine, technical innovation in product development among other factors are expected to drive the liquid biopsy in cancer diagnostics market.

Liquid Biopsy in Cancer Diagnostics Market Dynamics:

One of the key aspects driving the liquid biopsy in cancer diagnostics market is the growing demand for liquid biopsy in cancer diagnostics due to increase in the cancer incidence. As per the GLOBOCAN study conducted by the International Agency for Research on Cancer, in 2020, an estimated number of 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) and near about 10.0 million cancer deaths were reported globally. The above-mentioned source further stated that in 2020, lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Considering the increase in the number of new cancer cases all over the globe, there has been a growing emphasis on developing an alternative to conventional biopsies to facilitate the cancer diagnosis process and make it smoother for both patients and healthcare providers. Furthermore, the application of liquid biopsy in therapy management for cancers such as lung and breast is further expected to boost the product demand. Thus, the increasing patient population of cancers would, in turn, lead to an increase in demand for liquid biopsy products and services. Therefore, all the aforementioned factors are projected to contribute to the growth of liquid biopsy in the cancer diagnostics market.

Furthermore, another key contributor in the growing demand for liquid biopsy in cancer diagnostics is the increasing prominence of precision medicine in cancer care. The concept of "precision medicine" or individualizing the treatment plan according to the biological behavior of the tumor is considered a new approach in cancer management. The clinical applications of precision medicine are diverse encompassing screening, diagnosis, prognosis, prediction of treatment response and resistance, early detection of recurrence/metastasis, and biologic cancer stratification. Liquid biopsies hold great promise for personalized medicine due to their ability to provide multiple non-invasive global snapshots of the primary and metastatic tumors. The customization of treatment specific to the patient's health condition has gained widespread acceptance and attention from physicians. Liquid biopsy plays an important role in developing customized treatments for patients. It provides vital real-time information about the tumor profile and helps decide the subsequent steps in the treatment. The potential of liquid biopsy is also being realized by market players, which is evident by their growing interest in product development in this domain. For instance, in September 2022, German firm Molecular Health GmbH collaborated with a South Korean startup EONE-Diagnomics Genome Center (EDGC) to help its healthcare provider customers identify personalized treatment options for cancer patients. Therefore, the growing prominence of precision medicine and the advantages of liquid biopsy are expected to contribute to the growth of liquid biopsy in the cancer diagnostics market during the forecast period.

However, risk of false results due to procedural limitations and lack of standardization of procedures may be certain challenging aspects for the liquid biopsy in cancer diagnostics market growth.

The liquid biopsy in cancer diagnostics market witnessed a dip in the generated revenue due to the implementation of measures to curb the spread of the COVID-19 infection. One of the major steps during the COVID surge was the suspension of numerous elective procedures and outpatient visits which reduced the demand for liquid biopsy products and services in the market as the healthcare system guidelines across the globe temporarily focused all their efforts on the management of COVID-19 infection patient load during the initial lockdown period. As per the data provided by the Cancer Research UK, in the UK alone, for example, urgent lung cancer referrals fell by up to 75% during the first lockdown. This did not correlate to the decrease in cases, but that fewer people sought and obtained the diagnosis they urgently need. Unfortunately, these trends were prominent across countries around the globe. Nevertheless, the market for liquid biopsy in cancer diagnostics is on a period of recovery owing to devising of strategies to transform cancer care during the pandemic and approval of liquid biopsy products such as Exosomal liquid biopsy prostate test in March 2022 by the US Food and Drug Administration thereby presenting a future outlook for the liquid biopsy in cancer diagnostics market during the forecast period.

Liquid Biopsy in Cancer Diagnostics Market Segment Analysis:

Liquid Biopsy in Cancer Diagnostics Market by Type (Product Type [Instruments and Reagents & Kits] and Services), by Sample Type (Blood, Urine, and Saliva), by Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, and Others), by Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, and Others), by Technique (Polymerase Chain Reaction and Next Generation Sequencing), by End User (Hospitals, Diagnostic Centers, and Others), by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the liquid biopsy in cancer diagnostics market, the services category is accounted for 73% of market revenue share in 2020. This can be ascribed to various aspects of services catered by this category. Many companies are operating in the domain where they offer services pertaining to liquid biopsy ranging from sample collection to NGS analysis. One such example is an Australia-based company, BARD1 that offers a sample preparation platform called NETs Biomarker Capture Platform. This platform is a patented technology of the company to revolutionize the performance of liquid biopsy diagnostic assays.

Another such company catering to the services aspect of the liquid biopsy domain is Biodesix. The company offers a wide range of services from clinical aspects to clients from a research background. For instance, the company employs blood-based, multiple technologies approaches for diagnostic research to uncover novel insights about the tumor biology and patient's immune response to cancer for biopharmaceutical therapeutics in clinical development. Therefore, considering the wide application area of services aspect of the liquid biopsy domain, the service category is expected to account for a formidable market share in the liquid biopsy in the cancer diagnostics market.

North America is expected to dominate the overall Liquid Biopsy in Cancer Diagnostics Market:

Among all the regions, North America is expected to account for the significant market share in the liquid biopsy in cancer diagnostics market. North America is estimated to account for the dominant market share because of the increasing prevalence of cancers, increasing focus on oncology research, supportive government policies promoting liquid biopsy research and a conducive environment for product development and launches among other factors in the region.

Among all the North American countries, United States accounted for 87% of revenue share in the North America liquid biopsy in cancer diagnostics market in 2020. One of the key reasons for high uptake of liquid biopsy products and services in the country was the high prevalence of cancers. For instance, according to the data provided by the National Cancer institute (United States), till April 2022, bladder, breast, colon and rectal, endometrial and kidney cancer were some of the common cancer types in the country. Besides, the high prevalence of Cancer, United States is considered as one of the key countries that invests heavily in healthcare services as well as medical research. The US Food and Drug Administration also provides a supportive environment for new technologies to reach the market with the provision of "breakthrough device" designation to emerging technologies and products in the medical devices domain. For instance, in April 2022, the US FDA awarded the breakthrough device designation to Inviata Limited for their liquid biopsy product for minimal residue disease (MRD) test. The regulatory body also awarded the same designation to Bluestar Genomics' noninvasive pancreatic cancer detection test.

Additionally, cancer diagnosis and treatment can be extremely cost intensive for patients even after medical insurance. The coverage of liquid biopsy test in insurance and reimbursement programs offered by the US government further acts as a booster for their uptake by end users. For instance, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer is covered under CMS National Coverage Policy. Thus, all the above-stated factors are expected to drive the market for liquid biopsy in cancer diagnostics in the United States.

Moreover, the increasing prevalence of lifestyle disorders that present as major risk factors in cancer development. For instance, as per the data provided by the Global Obesity Observatory (2023), Mexico presents a national risk of obesity development on a scale of 10 to be 8. This represents that the majority of the population in Mexico either falls in the bracket of the obese population or is highly susceptible to being obese in the coming years. Many studies have established that excess body fat increases the risk for several cancers, including colorectal, postmenopausal breast, uterine, esophageal, kidney, and pancreatic cancers. Additionally, the increase in aging population in the country is also said to contribute to cancer incidence. According to the 2022 data published by the World Bank Group, approximately 9,822,231 population in Mexico were aged 65 years and above in 2020. Therefore, the increasing prevalence of risk factors such as obesity and aging that may play a crucial role in cancer development has also resulted in the country's increasing prevalence of various cancers. This has been a major driving factor for the growing demand for liquid biopsy products and services in Mexico.

Liquid Biopsy in Cancer Diagnostics Market Key Players:

Some of the key market players operating in the liquid biopsy in cancer diagnostics market includes Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd. and others.

Recent Developmental Activities in Liquid Biopsy In Cancer Diagnostics Market:

In October 2022, Sysmex Inostics developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML). This new test, AML-MRD-SEQ, adds to the portfolio of ultra-sensitive Plasma-Safe-SeqS technology NGS tests available through Sysmex Inostics' CLIA lab services in Baltimore, Maryland in the United States.

In June 2022, NeoGenomics completed its acquisition for Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England.

In January 2022, Exact Sciences Corporation acquired Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to developing a blood-based, multi-cancer screening test.

Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report Study

Market analysis for current liquid biopsy in cancer diagnostics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the liquid biopsy in cancer diagnostics market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the global liquid biopsy in cancer diagnostics market.

Various opportunities available for the other competitor in the liquid biopsy in cancer diagnostics market space.

What are the top performing segments in 2023? How these segments will perform in 2030.

Which is the top-performing regions and countries in the current liquid biopsy in cancer diagnostics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for liquid biopsy in cancer diagnostics market growth in the coming future?

Target Audience who can be benefited from this Liquid Biopsy in Cancer Diagnostics Market Report Study

Liquid Biopsy in Cancer Diagnostics products providers

Research organizations and consulting companies

Liquid Biopsy in Cancer Diagnostics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in liquid biopsy in cancer diagnostics

Various End-users who want to know more about the liquid biopsy in cancer diagnostics market and latest technological developments in the liquid biopsy in cancer diagnostics market.

Frequently Asked Questions for Liquid Biopsy in Cancer Diagnostics Market:

1. What is Liquid Biopsy?

A liquid biopsy is a test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy. It is most commonly applied to the collection of peripheral blood for analysis of cell-free circulating tumor deoxyribonucleic acids (DNA).

2. What is the market for Global Liquid Biopsy in Cancer Diagnostics?

Global liquid biopsy in cancer diagnostics market was valued at USD 7.64 billion in 2023, growing at a CAGR of 16.64% during the forecast period from 2024 to 2030 to reach USD 19.24 billion by 2030.

3. What are the drivers for Global Liquid Biopsy in Cancer Diagnostics Market?

Factors such as the rising incidence of various cancers, growing demand for minimally invasive procedures, increasing prominence of precision medicine, technical innovation in product development among other factors are expected to drive the liquid biopsy in cancer diagnostics market.

4. Who are the key players operating in Global Liquid Biopsy in Cancer Diagnostics Market?

Some of the key market players operating in the liquid biopsy in cancer diagnostics market includes Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd. and others.

5. Which region has the highest share in Liquid Biopsy in Cancer Diagnostics market?

North America is estimated to account for the dominant market share because of the increasing prevalence of cancers, increasing focus on oncology research, supportive government policies promoting liquid biopsy research and a conducive environment for product development and launches among other factors in the region.

Table of Contents

1.Liquid Biopsy in Cancer Diagnostics Market Report Introduction

2.Liquid Biopsy in Cancer Diagnostics Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Liquid Biopsy in Cancer Diagnostics Market Key Factor Analysis

  • 4.1 Liquid Biopsy in Cancer Diagnostics Market Drivers
    • 4.1.1 Rising Incidence of Various Cancers
    • 4.1.2 Growing Demand for Minimally Invasive Procedures
    • 4.1.3 Growing Prominence of Precision Medicine
    • 4.1.4 Technical Innovation in Product Development
  • 4.2 Liquid Biopsy in Cancer Diagnostics Market Restraints and Challenges
    • 4.2.1 Risk of False Results
    • 4.2.2 Lack of Standardization of Procedures
  • 4.3 Liquid Biopsy in Cancer Diagnostics Market Opportunities
    • 4.3.1 Limited Utilization of Liquid Biopsy in Clinical Settings
    • 4.3.2 Expanding Market Reach in Emerging Economies

5. Liquid Biopsy in Cancer Diagnostics Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Liquid Biopsy in Cancer Diagnostics Market

7. Liquid Biopsy in Cancer Diagnostics Market Layout

  • 7.1 By Type
    • 7.1.1 Products
      • 7.1.1.1 Reagents & Kits
      • 7.1.1.2 Instruments
    • 7.1.2 Services
  • 7.2 By Sample Type
    • 7.2.1 Blood
    • 7.2.2 Urine
    • 7.2.3 Saliva
  • 7.3 By Biomarker Type
    • 7.3.1 Circulating Tumor Cells (CTCs)
    • 7.3.2 Circulating Tumor DNA (ctDNA)
    • 7.3.3 Circulating Free DNA (cfDNA)
    • 7.3.4 Others
  • 7.4 By Cancer Type
    • 7.4.1 Lung Cancer
    • 7.4.2 Breast Cancer
    • 7.4.3 Colon Cancer
    • 7.4.4 Others
  • 7.5 By Technique
    • 7.5.1 Polymerase Chain Reaction
    • 7.5.2 Next Generation Sequencing
  • 7.6 By End User
    • 7.6.1 Hospitals
    • 7.6.2 Diagnostic Centers
    • 7.6.3 Others
  • 7.7 By Geography
    • 7.7.1 North America
      • 7.7.1.1 North America Liquid Biopsy in Cancer Diagnostics Market, by Country
      • 7.7.1.1.1 United States
      • 7.7.1.1.2 Canada
      • 7.7.1.1.3 Mexico
    • 7.7.2 Europe
      • 7.7.2.1 Europe Liquid Biopsy in Cancer Diagnostics Market, by Country
      • 7.7.2.1.1 France
      • 7.7.2.1.2 Germany
      • 7.7.2.1.3 United Kingdom
      • 7.7.2.1.4 Italy
      • 7.7.2.1.5 Spain
      • 7.7.2.1.6 Russia
      • 7.7.2.1.7 Rest of Europe
    • 7.7.3 Asia-Pacific
      • 7.7.3.1 Asia-Pacific Liquid Biopsy in Cancer Diagnostics Market, by Country
      • 7.7.3.1.1 China
      • 7.7.3.1.2 Japan
      • 7.7.3.1.3 India
      • 7.7.3.1.4 Australia
      • 7.7.3.1.5 South Korea
      • 7.7.3.1.6 Rest of Asia Pacific
    • 7.7.4 Rest of the World (RoW)
      • 7.7.4.1 RoW Liquid Biopsy in Cancer Diagnostics Market, by Region
      • 7.7.4.1.1 Middle East
      • 7.7.4.1.2 Africa
      • 7.7.4.1.3 South America

8. Liquid Biopsy in Cancer Diagnostics Market Company and Product Profiles

  • 8.1 Myriad Genetics Inc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5. Entropy
  • 8.2 Exact Sciences Corporation
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5. Entropy
  • 8.3 Biocartis
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5. Entropy
  • 8.4 Sysmex Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5. Entropy
  • 8.5 Thermo Fisher Scientific Inc
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5. Entropy
  • 8.6 Biocept Inc
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5. Entropy
  • 8.7 Agilent Technologies Inc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5. Entropy
  • 8.8 MDx Health
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5. Entropy
  • 8.9 Neogenomics Laboratories
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5. Entropy
  • 8.10 F. Hoffman La Roche Ltd
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5. Entropy
  • 8.11 Guardant Health
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5. Entropy
  • 8.12 Bio-Techne
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5. Entropy
  • 8.13 Illumina Inc
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5. Entropy
  • 8.14 QIAGEN
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5. Entropy
  • 8.15 Lucence Health Inc
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5. Entropy
  • 8.16 Personal Genome Diagnostics Inc
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5. Entropy
  • 8.17 SAGA Diagnostics
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5. Entropy
  • 8.18 Agena Bioscience Inc
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5. Entropy
  • 8.19 The Menarini Group
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5. Entropy
  • 8.20 MiRXES Pte Ltd.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Bibliography

10. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Liquid Biopsy in Cancer Diagnostics Market
  • Table 3 Liquid Biopsy in Cancer Diagnostics Market in Global (2021-2030)
  • Table 4 Liquid Biopsy in Cancer Diagnostics Market in Global by Type (2021-2030)
  • Table 5 Liquid Biopsy in Cancer Diagnostics Market in Global by Sample Type (2021-2030)
  • Table 6 Liquid Biopsy in Cancer Diagnostics Market in Global by Biomarker Type (2021-2030)
  • Table 7 Liquid Biopsy in Cancer Diagnostics Market in Global by Cancer Type (2021-2030)
  • Table 8 Liquid Biopsy in Cancer Diagnostics Market in Global by Technique (2021-2030)
  • Table 9 Liquid Biopsy in Cancer Diagnostics Market in Global by End User (2021-2030)
  • Table 10 Liquid Biopsy in Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Table 11 Liquid Biopsy in Cancer Diagnostics Market in North America (2021-2030)
  • Table 18 Liquid Biopsy in Cancer Diagnostics Market in the US (2021-2030)
  • Table 19 Liquid Biopsy in Cancer Diagnostics Market in Canada (2021-2030)
  • Table 20 Liquid Biopsy in Cancer Diagnostics Market in Mexico (2021-2030)
  • Table 21 Liquid Biopsy in Cancer Diagnostics Market in Europe (2021-2030)
  • Table 29 Liquid Biopsy in Cancer Diagnostics Market in France (2021-2030)
  • Table 30 Liquid Biopsy in Cancer Diagnostics Market in Germany (2021-2030)
  • Table 31 Liquid Biopsy in Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Table 32 Liquid Biopsy in Cancer Diagnostics Market in Italy (2021-2030)
  • Table 33 Liquid Biopsy in Cancer Diagnostics Market in Spain (2021-2030)
  • Table 34 Liquid Biopsy in Cancer Diagnostics Market in Russia (2021-2030)
  • Table 35 Liquid Biopsy in Cancer Diagnostics Market in Rest of Europe (2021-2030)
  • Table 36 Liquid Biopsy in Cancer Diagnostics Market in APAC (2021-2030)
  • Table 44 Liquid Biopsy in Cancer Diagnostics Market in China (2021-2030)
  • Table 45 Liquid Biopsy in Cancer Diagnostics Market in Japan (2021-2030)
  • Table 46 Liquid Biopsy in Cancer Diagnostics Market in India (2021-2030)
  • Table 47 Liquid Biopsy in Cancer Diagnostics Market in Australia (2021-2030)
  • Table 48 Liquid Biopsy in Cancer Diagnostics Market in South Korea (2021-2030)
  • Table 49 Liquid Biopsy in Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Table 50 Liquid Biopsy in Cancer Diagnostics Market in Rest of World (2021-2030)
  • Table 58 Liquid Biopsy in Cancer Diagnostics Market in Middle East (2021-2030)
  • Table 59 Liquid Biopsy in Cancer Diagnostics Market in Africa (2021-2030)
  • Table 60 Liquid Biopsy in Cancer Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Liquid Biopsy in Cancer Diagnostics Market
  • Figure 3 Liquid Biopsy in Cancer Diagnostics Market in Global (2021-2030)
  • Figure 4 Liquid Biopsy in Cancer Diagnostics Market in Global by Type (2021-2030)
  • Figure 5 Liquid Biopsy in Cancer Diagnostics Market in Global by Sample Type (2021-2030)
  • Figure 6 Liquid Biopsy in Cancer Diagnostics Market in Global by Biomarker Type (2021-2030)
  • Figure 7 Liquid Biopsy in Cancer Diagnostics Market in Global by Cancer Type (2021-2030)
  • Figure 8 Liquid Biopsy in Cancer Diagnostics Market in Global by Technique (2021-2030)
  • Figure 9 Liquid Biopsy in Cancer Diagnostics Market in Global by End User (2021-2030)
  • Figure 10 Liquid Biopsy in Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Figure 11 Liquid Biopsy in Cancer Diagnostics Market in North America (2021-2030)
  • Figure 18 Liquid Biopsy in Cancer Diagnostics Market in the US (2021-2030)
  • Figure 19 Liquid Biopsy in Cancer Diagnostics Market in Canada (2021-2030)
  • Figure 20 Liquid Biopsy in Cancer Diagnostics Market in Mexico (2021-2030)
  • Figure 21 Liquid Biopsy in Cancer Diagnostics Market in Europe (2021-2030)
  • Figure 29 Liquid Biopsy in Cancer Diagnostics Market in France (2021-2030)
  • Figure 30 Liquid Biopsy in Cancer Diagnostics Market in Germany (2021-2030)
  • Figure 31 Liquid Biopsy in Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 32 Liquid Biopsy in Cancer Diagnostics Market in Italy (2021-2030)
  • Figure 33 Liquid Biopsy in Cancer Diagnostics Market in Spain (2021-2030)
  • Figure 34 Liquid Biopsy in Cancer Diagnostics Market in Russia (2021-2030)
  • Figure 35 Liquid Biopsy in Cancer Diagnostics Market in Rest of Europe (2021-2030)
  • Figure 36 Liquid Biopsy in Cancer Diagnostics Market in APAC (2021-2030)
  • Figure 44 Liquid Biopsy in Cancer Diagnostics Market in China (2021-2030)
  • Figure 45 Liquid Biopsy in Cancer Diagnostics Market in Japan (2021-2030)
  • Figure 46 Liquid Biopsy in Cancer Diagnostics Market in India (2021-2030)
  • Figure 47 Liquid Biopsy in Cancer Diagnostics Market in Australia (2021-2030)
  • Figure 48 Liquid Biopsy in Cancer Diagnostics Market in South Korea (2021-2030)
  • Figure 49 Liquid Biopsy in Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 50 Liquid Biopsy in Cancer Diagnostics Market in Rest of World (2021-2030)
  • Figure 58 Liquid Biopsy in Cancer Diagnostics Market in Middle East (2021-2030)
  • Figure 59 Liquid Biopsy in Cancer Diagnostics Market in Africa (2021-2030)
  • Figure 60 Liquid Biopsy in Cancer Diagnostics Market in South America (2021-2030)
  • Figure 61 Market Drivers
  • Figure 62 Market Barriers
  • Figure 63 Marker Opportunities
  • Figure 64 PORTER'S Five Force Analysis